PMID- 28752092
OWN - NLM
STAT- MEDLINE
DCOM- 20180405
LR  - 20181113
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2017
DP  - 2017
TI  - Automated Image Analysis of HER2 Fluorescence In Situ Hybridization to Refine 
      Definitions of Genetic Heterogeneity in Breast Cancer Tissue.
PG  - 2321916
LID - 10.1155/2017/2321916 [doi]
LID - 2321916
AB  - Human epidermal growth factor receptor 2 gene- (HER2-) targeted therapy for 
      breast cancer relies primarily on HER2 overexpression established by 
      immunohistochemistry (IHC) with borderline cases being further tested for 
      amplification by fluorescence in situ hybridization (FISH). Manual interpretation 
      of HER2 FISH is based on a limited number of cells and rather complex definitions 
      of equivocal, polysomic, and genetically heterogeneous (GH) cases. Image analysis 
      (IA) can extract high-capacity data and potentially improve HER2 testing in 
      borderline cases. We investigated statistically derived indicators of HER2 
      heterogeneity in HER2 FISH data obtained by automated IA of 50 IHC borderline 
      (2+) cases of invasive ductal breast carcinoma. Overall, IA significantly 
      underestimated the conventional HER2, CEP17 counts, and HER2/CEP17 ratio; 
      however, it collected more amplified cells in some cases below the lower limit of 
      GH definition by manual procedure. Indicators for amplification, polysomy, and 
      bimodality were extracted by factor analysis and allowed clustering of the tumors 
      into amplified, nonamplified, and equivocal/polysomy categories. The bimodality 
      indicator provided independent cell diversity characteristics for all clusters. 
      Tumors classified as bimodal only partially coincided with the conventional GH 
      heterogeneity category. We conclude that automated high-capacity nonselective 
      tumor cell assay can generate evidence-based HER2 intratumor heterogeneity 
      indicators to refine GH definitions.
FAU - Radziuviene, Gedmante
AU  - Radziuviene G
AD  - National Center of Pathology, Affiliate of Vilnius University Hospital 
      Santariskiu Clinics, P. Baublio 5, LT-08406 Vilnius, Lithuania.
AD  - Faculty of Natural Sciences, Vilnius University, M. K. Ciurlionio 27, LT-03103 
      Vilnius, Lithuania.
FAU - Rasmusson, Allan
AU  - Rasmusson A
AD  - National Center of Pathology, Affiliate of Vilnius University Hospital 
      Santariskiu Clinics, P. Baublio 5, LT-08406 Vilnius, Lithuania.
FAU - Augulis, Renaldas
AU  - Augulis R
AD  - National Center of Pathology, Affiliate of Vilnius University Hospital 
      Santariskiu Clinics, P. Baublio 5, LT-08406 Vilnius, Lithuania.
AD  - Faculty of Natural Sciences, Vilnius University, M. K. Ciurlionio 27, LT-03103 
      Vilnius, Lithuania.
AD  - Faculty of Medicine, Vilnius University, M. K. Ciurlionio 21, LT-03101 Vilnius, 
      Lithuania.
FAU - Lesciute-Krilaviciene, Daiva
AU  - Lesciute-Krilaviciene D
AD  - National Center of Pathology, Affiliate of Vilnius University Hospital 
      Santariskiu Clinics, P. Baublio 5, LT-08406 Vilnius, Lithuania.
AD  - Faculty of Natural Sciences, Vilnius University, M. K. Ciurlionio 27, LT-03103 
      Vilnius, Lithuania.
FAU - Laurinaviciene, Aida
AU  - Laurinaviciene A
AD  - National Center of Pathology, Affiliate of Vilnius University Hospital 
      Santariskiu Clinics, P. Baublio 5, LT-08406 Vilnius, Lithuania.
AD  - Faculty of Medicine, Vilnius University, M. K. Ciurlionio 21, LT-03101 Vilnius, 
      Lithuania.
FAU - Clim, Eduard
AU  - Clim E
AD  - TissueGnostics, Vienna, Austria.
FAU - Laurinavicius, Arvydas
AU  - Laurinavicius A
AUID- ORCID: 0000-0001-9232-1730
AD  - National Center of Pathology, Affiliate of Vilnius University Hospital 
      Santariskiu Clinics, P. Baublio 5, LT-08406 Vilnius, Lithuania.
AD  - Faculty of Medicine, Vilnius University, M. K. Ciurlionio 21, LT-03101 Vilnius, 
      Lithuania.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20170528
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - *Automation, Laboratory
MH  - Breast Neoplasms/*genetics/pathology
MH  - Carcinoma, Ductal, Breast/*genetics/pathology
MH  - Female
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence/instrumentation/methods
MH  - Receptor, ErbB-2/*genetics
PMC - PMC5511668
EDAT- 2017/07/29 06:00
MHDA- 2018/04/06 06:00
PMCR- 2017/05/28
CRDT- 2017/07/29 06:00
PHST- 2016/12/19 00:00 [received]
PHST- 2017/03/20 00:00 [revised]
PHST- 2017/04/26 00:00 [accepted]
PHST- 2017/07/29 06:00 [entrez]
PHST- 2017/07/29 06:00 [pubmed]
PHST- 2018/04/06 06:00 [medline]
PHST- 2017/05/28 00:00 [pmc-release]
AID - 10.1155/2017/2321916 [doi]
PST - ppublish
SO  - Biomed Res Int. 2017;2017:2321916. doi: 10.1155/2017/2321916. Epub 2017 May 28.